Angela Lopez

Dr. Angela Lopez

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2020 in JACC: Cardiovascular Imaging
Verified
Journal Article
Closed access
MBMichele Boldrini
Michele Boldrini
FCFrancesco Cappelli
Francesco Cappelli
LCLiza Chacko
Liza Chacko
MRMaria Alejandra Restrepo-Cordoba
Maria Alejandra Restrepo-Cordoba
ALAngela Lopez
Angela Lopez
MFMarianna Fontana
Marianna Fontana

1 November 2018 in JACC
Verified
Journal Article
Closed access
FDFernando Domínguez
Fernando Domínguez
SCSofía Cuenca
Sofía Cuenca
ZBZofia Bilińska
Zofia Bilińska
EVEric Villard
Eric Villard
RBRoberto Barriales-Villa
Roberto Barriales-Villa
DDDennis Dooijes
Dennis Dooijes

1 July 2020 in JACC
Verified
Journal Article
Closed access
ALAngela Lopez
Angela Lopez
FDFernando Dominguez
Fernando Dominguez
LLLuis Rocha Lopes
Luis Rocha Lopes
JOJuan Pablo Ochoa
Juan Pablo Ochoa
RBRoberto Barriales-Villa
Roberto Barriales-Villa
DDDennis Dooijes
Dennis Dooijes

5 June 2017 in European Journal of Heart Failure
Verified
Journal Article
Closed access
PDF file
ALAngela Lopez
Angela Lopez
EBEduardo Barge-Caballero
Eduardo Barge-Caballero
GBGonzalo Barge-Caballero
Gonzalo Barge-Caballero
DCDavid Couto-Mallón
David Couto-Mallón
MPMaría J. Paniagua-Martin
María J. Paniagua-Martin
MCMaría G. Crespo-Leiro
María G. Crespo-Leiro

1 November 2017 in Revista Española de Cardiología (English Edition)
Verified
Journal Article
Closed access
EGEsther González-López
Esther González-López
ALAngela Lopez
Angela Lopez
PGPablo Garcia-Pavia
Pablo Garcia-Pavia

7 June 2019 in Amyloid
Verified
Journal Article
Closed access
ALAngela Lopez
Angela Lopez
FMF. Javier de Haro-Del Moral
F. Javier de Haro-Del Moral
FDFernando Dominguez
Fernando Dominguez
ARAlejandra Restrepo-Cordoba
Alejandra Restrepo-Cordoba
AAAlmudena Amor-Salamanca
Almudena Amor-Salamanca
PGPablo Garcia-Pavia
Pablo Garcia-Pavia
Objective: Cardiac amyloid infiltration can lead to systolic heart failure (HF) or to conduction disorders (CD). Patients with transthyretin (ATTR) amyloidosis are particularly exposed. We sought to determine the prevalence of ATTR and AL among patients >60 years admitted with CD or unexplained systolic HF and increased wall thickness. Materials and Methods: We studied 143 patients (57% males, 79 ± 9 years) with HF (N = 28) or CD requiring pacemaker implantation (N = 115). In total, 139 (97%) patients (28 with HF and 111 with CD) underwent 99mTc-DPD scintigraphy to detect ATTR, and 105 (73%; 19 HF and 86 CD) underwent AL screening. Results: Five patients (4%; 95%CI:0–7%) exhibited wild-type ATTR (ATTRwt) amyloidosis, 2 (2%; 95%CI:0–4%) had CD and 3 (11%; 95%CI:0–23%) HF. No patient showed AL. The 2 ATTRwt patients with CD were previously asymptomatic, did not show classical ECG signs and exhibited mild LV hypertrophy with preserved LVEF. By contrast, all ATTRwt patients with HF had ECG and echocardiographic signs of amyloid. During a mean follow-up of 18 ± 11 months, 3(60%) patients with ATTRwt amyloidosis (1 CD and 2 HF) and 14(10.4%) without died. Conclusion: Prevalence of ATTRwt amyloidosis in patients with CD requiring pacemaker is low. Although, additional studies are needed, prevalence seems to be higher in elderly patients with systolic HF.